Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans

ROCKVILLE, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the...
August 07, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results

Presented Preliminary Clinical Data on RX-3117 in Bladder Cancer at the American Society of Clinical Oncologists (ASCO) Annual Meeting Strengthened Financial Position with a $10 million Registered...
July 10, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117

ROCKVILLE, Md., July 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
June 07, 2017 08:50 ET | Source: Rexahn Pharmaceuticals

Rexahn Announces $10 Million Registered Direct Offering

ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into definitive agreements with institutional investors to purchase...
June 04, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Metastatic Bladder Cancer Resistant to Gemcitabine who had Failed on Multiple Prior...
May 08, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

ROCKVILLE, Md., May 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
May 05, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Effects 1-for-10 Reverse Stock Split

ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (“Rexahn” or the “Company”), a clinical stage biopharmaceutical company developing innovative, targeted...
May 04, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

Completed Phase I dose-escalation study with Supinoxin™ in solid tumors Initiated Phase IIa clinical trial of Supinoxin in Metastatic Triple Negative Breast Cancer ROCKVILLE, Md., May 04, 2017 ...
April 13, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Announces 1-for-10 Reverse Stock Split

ROCKVILLE, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
February 27, 2017 09:00 ET | Source: Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update

Progressed Three Novel Targeted Anti-Cancer Therapies in Clinical Development Completed stage 1 and initiated stage 2 of Phase IIa clinical trial of RX-3117 in Relapsed and Refractory Metastatic...